2021CCIF|Memo series products made a splash at the 24th National Interventional Cardiology Forum

Professor Jing Zhicheng presented Latest Application Progress of MemoCarna® ASD Occluder III (Oxide Coating), and specified two major upgrades of MemoCarna's single-rivet design and oxide coating treatment process, and their excellent marketing performance in clinical applications.

Professor Jiang Xiaofei presented Sharing of MemoLefort® LAA Closure Occluder I Operating Skills. By specifying its clinical application cases, he introduced features and operating skills of MemoLefort, a domestic occluder with a plug design, in comprehensible languages. He indicated that 'MemoLefort's design caters to clinical needs, is easy to operate, and has a short learning curve. It needs to be promoted on a standardized basis to garner more clinical application data.'

With reference to her experience of ASD/PFO integrated LAAC closure 'one-stop' surgery, professor He Lu gave a wonderful lecture on Treatment Strategies and MemoLefort Clinical Application Experience for Congenital Heart Disease and Atrial Fibrillation.

At the conference, Professor Fang Weiwei, Zhou Daxin, Ning Zhongping and Hu Hao also presented wonderful comments on Memo series products and treatment of congenital heart disease and left atrial appendage occlusion. To conclude, Professor Zhou Daxin summed up that 'with joint efforts of Chinese clinicians and domestic manufacturers, domestically-made occlusion devices have grown from admiring imported devices to now being on par with imported devices. Hopefully our domestically-made devices will be catching up in being innovative and quality-oriented. and achieve the goal of replacing the imports.

In the 'MemoCarna Oxide-coated ASD Occluder Seminar', Professor Qin Yongwen elaborated 5 major advantages of MemoCarna namely: ①Patented mold locking structure to ensure secure and firm clamping;②More flattened discs to improve endothelialization; ③Single-rivet design to reduce metal implants and load to the heart; ④Uniform and dense oxide coating produced under plasma treatment process to minimize the precipitation of nickel ions; and; ⑤Braided mesh to preserve a pathway for future transseptal treatments.

After that, 4 other professors presented wonderful case sharing. Starting from anatomical characteristics and plugging elements of ASD, Professor Jiang Xiaofei referred to his experience in more than 50 occlusion procedures using MemoCarna in a single-centered clinical trial, and focused on excellent molding and clamping capabilities of the oxide-coated single-rivet occluder. Based on his pragmatic experience on how to make puncture when ASD patients need to undergo transatrial septal puncture after the closure, Professor Wang Cheng analyzed unique weaving of MemoCarna's left disc that leaves a pathway between the wires to reserve the unique advantage of leaving more space for transatrial septal puncture in the future. Professor Jin Bowen shared a case of headache due to incomplete endothelialization after traditional double-rivet ASD occlusion, and further discussed advantages of oxide-coated single-rivet ASD occluder which is more conducive to endothelialization and reducing of precipitation of nickel ions, and he mentioned that the oxide-coated single-rivet ASD occluder outperformed traditional single-rivet ASD occluder in terms of molding and resilience performance. Professor Hongwei Zhang presented a case of atrial fibrillation after ASD closure, and re-discussed the unique advantages of MemoCarna® ASD Occluder III (Oxide Coating) in future transatrial septal puncture treatments.

By revolving upon case sharing and unique advantages of MemoCarna, participating experts engaged in a lively discussion and made wonderful comments. Expertsonce again expressed their affirmation and expectations for MemoCarna and aspired that more excellent domestic devices will pop up in days to come.